Reviewed by Michael Gill, B. Sc.
25 Osteoporosis Clinical Trials Near Me
Top Hospitals for Osteoporosis Clinical Trials
Image of Kessler Institute for Rehabilitation in New Jersey.
Kessler Institute for Rehabilitation
West Orange
3Active Trials
5All Time Trials for Osteoporosis
2006First Osteoporosis Trial
Image of James J. Peters VA Medical Center in New York.
James J. Peters VA Medical Center
Bronx
3Active Trials
4All Time Trials for Osteoporosis
2015First Osteoporosis Trial
Top Cities for Osteoporosis Clinical Trials
Image of Chicago in Illinois.
Chicago
6Active Trials
Northwestern University Feinberg School of MedicineTop Active Site
Top Treatments for Osteoporosis Clinical Trials
Treatment Name
Active Osteoporosis Clinical Trials
All Time Trials for Osteoporosis
First Recorded Osteoporosis Trial
Romosozumab
4
15
2009
Denosumab
3
46
2003
Supervised strength training (group 1)
1
1
2022
Surgical Intervention
1
1
2022
Exercise
1
8
1998
Recently Completed Studies with FDA Approved Treatments for Osteoporosis
Treatment
Year
Sponsor
GP2411
2019
Sandoz
Calcium and vitamin D
2015
Masonic Cancer Center, University of Minnesota

What Are Osteoporosis Clinical Trials?

Osteoporosis is a skeletal health condition characterized by a decreased density of normally mineralized bone. The reduced bone mass leads to weakened, fragile bones that are more likely to fracture.

Cells are responsible for constantly breaking down (osteoclasts) and replacing (osteoblasts) bone. Osteoporosis occurs when the renewal production of bone tissue cannot keep up with the breakdown of old bone.

Osteoporosis can affect women and men of all races, but white and Asian women, especially those who are past menopause, are at the highest risk.

Why Is Osteoporosis Being Studied Through Clinical Trials?

Osteoporosis clinical trials aim to test the efficacy and safety of investigational drugs, medical devices, or treatments.

Researchers aim to identify the possible causes of osteoporosis and provide relief, prevent further complications, and ultimately cure osteoporosis in patients.

Approximately 10 million Americans are diagnosed with osteoporosis. In addition, another 44 million Americans have low bone density, placing them at high risk of bone fractures.

Up to one in two women and one in every four men will suffer from a bone fracture due to osteoporosis in their lifetime.

Clinical trials for osteoporosis are broadly divided into two categories:

  • Testing the efficacy and safety of new therapies, medicines, and treatments

  • Expanding knowledge and understanding of the different aspects and causes of osteoporosis

Individuals diagnosed with osteoporosis volunteer to test new drugs or procedures to determine if they are effective and safe.

What Are The Types of Treatments Available For Osteoporosis?

Osteoporosis is mainly treated with the following drugs:

  • Antiresorptive drugs: Slow down or blocks the breakdown of bone.

  • Anabolic drugs: Stimulates or enhance the formation of new bone.

Anabolic Therapy in Postmenopausal Osteoporosis

The clinical trial is to learn more about the effects of two FDA-approved medications, Romosozumab and Denosumab, in treating osteoporosis in postmenopausal women.

Exercise Training For Osteoporosis

The clinical study is a six-month randomized control study to identify complementary therapies to enhance the treatment of osteoporosis and low bone mass in older patients.

The study will examine the efficacy of novel progressive resistive muscle exercises in postmenopausal women with a low bone mass.

What Are Some Recent Breakthrough Clinical Trials For Osteoporosis?

2004: Teriparatide Reduces Fracture Risks Associated With Osteoporosis Fractures – Teriparatide (Forteo) is a synthetic version of parathyroid hormone that helps to increase bone density and strength. It is the first approved anabolic (bone-building) drug. Teriparatide stimulates bone formation and reduces fracture risks in the spine and other bones.

2016: Romosozumab Treatment in Postmenopausal Women with Osteoporosis – A trial in The New England Journal of Medicine enrolled over 7,000 postmenopausal women with osteoporosis and found that women using romosozumab had far fewer vertebral fractions compared to the placebo group.

Who Are Some Of The Key Opinion Leaders / Researchers In Osteoporosis Research?

Douglas C. Bauer, M.D. is a key researcher in the etiology, diagnosis, and treatment of osteoporosis. He was a Trustee for the National Osteoporosis Foundation and currently serves on the FDA Bone, Urologic, and Reproductive Drug Advisory Committee (BRUDAC).

Steven R. Cummings, M.D. is an internationally recognized specialist in the epidemiology of osteoporosis, aging, and women’s health.

Michael C. Nevitt, Ph.D., MPH, is a leading expert on the epidemiology of osteoarthritis of the knee and hip.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: November 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. Erratum in: Am J Respir Crit Care Med. 2016 May 15;193(10):1185. https://pubmed.ncbi.nlm.nih.gov/120911802 Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991 Feb;39(2):142-8. https://pubmed.ncbi.nlm.nih.gov/19919463 Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81. https://pubmed.ncbi.nlm.nih.gov/71548934 Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 Apr;89(4):780-5. https://pubmed.ncbi.nlm.nih.gov/174038005 Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377-81. https://pubmed.ncbi.nlm.nih.gov/71548936 Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP; American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011 Jul;43(7):1334-59. doi: 10.1249/MSS.0b013e318213fefb. https://pubmed.ncbi.nlm.nih.gov/216945567 Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869. https://pubmed.ncbi.nlm.nih.gov/203325118 Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869. https://pubmed.ncbi.nlm.nih.gov/203325119 Mizner RL, Petterson SC, Stevens JE, Vandenborne K, Snyder-Mackler L. Early quadriceps strength loss after total knee arthroplasty. The contributions of muscle atrophy and failure of voluntary muscle activation. J Bone Joint Surg Am. 2005 May;87(5):1047-53. https://pubmed.ncbi.nlm.nih.gov/1586696810 Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD007146. doi: 10.1002/14651858.CD007146.pub3. Review. https://pubmed.ncbi.nlm.nih.gov/22972103